)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Shionogi & Co
Shionogi & Co (4507) investor relations material
Shionogi & Co Q2 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2027 earnings summary29 Oct, 2026
Executive summary
H1 FY2026 revenue reached a record ¥350.4bn, up 64.5% YoY; operating profit and profit attributable to owners also set first-half records.
Growth investments and existing businesses supported stronger results; the edaravone acquisition expanded rare-disease capabilities, while ViiV equity-method earnings increased.
Financial highlights
H1 revenue was ¥350,377m (+64.5% YoY), operating profit ¥115,244m (+55.8%), core operating profit ¥132,694m (+75.7%) and EBITDA ¥174,556m (+103.4%).
Profit before tax rose 9.9% to ¥107,257m; profit attributable to owners rose 44.0% to ¥119,546m, with basic EPS of ¥140.47 versus ¥97.55.
Revenue exceeded the ¥340.0bn forecast; operating profit was ¥115.2bn versus ¥96.0bn forecast, and attributable profit was ¥119.5bn versus ¥108.0bn.
Operating cash flow was ¥142,166m; investing cash outflow was ¥434,663m, including ¥390,757m for the edaravone acquisition. Cash and equivalents fell ¥332,075m to ¥376,482m.
Q2 revenue rose 14.5% QoQ to ¥187.1bn; operating margin expanded 2.8 percentage points to 34.2%.
Outlook and guidance
Full-year guidance increased to revenue ¥720bn, operating profit ¥230bn, profit before tax ¥220.5bn and attributable profit ¥212.5bn; EBITDA guidance rose to ¥336bn.
Revenue and operating profit forecasts rose ¥20bn and ¥10bn, respectively; overseas subsidiaries/exports and royalty assumptions improved.
Domestic prescription-drug guidance fell ¥6.7bn to ¥172bn, reflecting acute respiratory infection drug shortfalls and slower Zurzuvae progress; forecast H2 operating profit was reduced ¥9.2bn to ¥114.8bn.
Forecasts include expected AQNEURSA sales, inventory costs and IntraBio intangible amortization; closing was expected in November–December 2026, subject to approvals and conditions.
SG&A is expected to rise with IntraBio amortization and U.S. growth investment; pipeline prioritization and cost control are planned.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Shionogi & Co
- Robust pipeline advances in infectious and QOL diseases drive growth and global expansion.4507
R&D Day 2024 presentation - Acquisition of JT Pharma, TORII, and Akros accelerates global R&D and innovation leadership.4507M&A presentation
- Global healthcare transformation targets 2030, powered by innovation and strengthened governance.4507Sustainability presentation
- Record Q1 revenue and profit growth driven by acquisitions and global sales expansion.4507Q1 2027
- Strong ROE and growth-focused strategies drive value, supported by robust governance and IR.4507Investor presentation
- Record revenue and profit growth driven by M&A, royalties, and new product launches.4507Q4 2026
- Record revenue and profit growth, driven by HIV, acquisitions, and strategic investments.4507Q3 2026
- Profit growth driven by HIV, overseas, and royalty income, with upward profit forecast revisions.4507Q2 2026
- Profit and revenue grew on HIV franchise and royalty income, with strong outlook and stable guidance.4507Q1 2026
Next Shionogi & Co earnings date
Q3 20275 Feb, 2027
Shionogi & Co
Next Shionogi & Co earnings date
Q3 20275 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Shionogi & Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of a wide range of pharmaceutical products. The company's core business areas include prescription drugs, over-the-counter medications, and diagnostic products. Shionogi focuses on therapeutic areas such as infectious diseases, pain management, and cardiovascular diseases. It also provides contract development and manufacturing services to other pharmaceutical companies. Shionogi & Co., Ltd. is headquartered in Osaka, Japan, and its shares are listed on the TYO.